Durvalumab is an IV drug that boosts the immune system’s ability to detect and kill cancer cells. It’s used to treat a range ...

Bristol Myers Squibb has agreed to pay up to $11.1 billion to partner with Germany's BioNTech and develop the latter's ...

A new study found the drug kept head and neck cancers at bay for five years compared to 30 months with standard care ...

Drugs that boost the body’s immune system to fight disease are showing promise in treating a variety of cancers in earlier ...

Results from a Phase III clinical trial published in the New England Journal of Medicine, show that patients with lung cancer ...

Tests in 1,225 patients with the most deadly form of skin cancer reveal for the first time a genetic trait among most of ...

Study examines treatment options for those with operable non-small cell lung cancer, the leading cause of cancer deaths ...

ASCO 2025 delivered pivotal updates. In this article, we discuss 8 of the more interesting abstracts from an investment ...

Results from a new study help resolve the decade-long mystery of why many patients with the deadliest form of skin cancer do ...

Reducing the length of immunotherapy treatment for an advanced skin cancer did not significantly diminish disease control ...

Head and neck cancer patients went disease-free for five years, compared to half that time for people undergoing standard ...

Hundreds of thousands of people with advanced head and neck cancer could live longer without their cancer returning thanks to ...